Mild cognitive impairment (MCI)

Displaying 30 studies

  • iTBS rTMS in Mild Cognitive Impairment Rochester, MN

    To test the feasibility of conducting a 10-day Intermittent Theta Burst Stimulation (iTBS) repetitive Transcranial Magnetic Stimulation (rTMS) protocol twice using a cross-over design in individuals with Mild Cognitive Impairment (MCI), pilot test the study protocol to assess study design, and collect pilot data on the effect of stimulations over 3 different brain regions (left dorsolateral prefrontal cortex (DLPFC), lateral parietal cortex (LPC), vertex (control)) on working memory, new-learning and executive function in MCI. Neuropsychological and sleep measures, functional brain magnetic resonance imaging (fMRI), high density EEG and questionnaires will be performed at 5 timepoints – (i) baseline, (ii) post-treatment after first ...

  • Physical Exercise And Cognitive Engagement Outcomes for Mild Neurocognitive Disorder Jacksonville, FL

    Behavioral interventions currently provide the most useful approach to addressing the behavioral and social needs of those with Mild Cognitive Impairment (MCI) due to Alzheimer's or other diseases. This randomized, multisite, 3-arm study will investigate the impact of computerized brain fitness vs yoga vs an active control group (wellness education) on changes in cognitive function, daily functioning and quality of life in persons with Mild Cognitive Impairment (MCI) and their partner. In addition, in vivo neuroimaging measures of plasticity during the pre- and post-intervention periods will be measured and compared between the three different treatment groups. These neuroimaging measures of ...

  • Cathodal tDCS in MCI: A Randomized, Double-Blind, Sham-Controlled Pilot Study Scottsdale/Phoenix, AZ

    The purpose of this study is to investigate whether giving transcranial direct current stimulation (tDCS) treatment using an investigational device called the Soterix tES Device (tDCS device) on the right side of the brain can improve performance on cognitive tests. Investigational means that the tDCS device is not approved by the U.S. Food and Drug Administration (FDA) for the use in this study.

  • HABIT Healthy Action to Benefit Independence and Thinking® Registry Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN; Scottsdale/Phoenix, AZ; La Crosse, WI

    The purpose of this study is to create this data repository as a mechanism to create a HABIT Registry that houses all retrospective and prospective HABIT-related data in a central database.

  • A Study to Address End-of-Life Disparities Among African Americans with Mild Cognitive Impairment and Dementia Jacksonville, FL

    The purpose of this study is to reduce disparities in end-of-life care by increasing engagement in advance care planning among African Americans with mild cognitive impairment and early dementia and their caregivers.

  • Study to Develop a Linguistically and Culturally Appropriate Adaptation of the Memory Support System (MSS) for Spanish-speaking Hispanics with Mild Cognitive Impairment (MCI) and their Care Partners in the U.S. Jacksonville, FL

    The purpose of this study is to develop a linguistically and culturally- appropriate adaptation of the memory support system (MSS) for Spanish-speaking Hispanics with subjective memory/cognitive complaints or a diagnosis of mild cognitive impairment (MCI) and their care partners in the U.S.

  • A Study to Evaluate the Safety and Effectiveness of Gantenerumab in Participants With Early Alzheimer's Disease (AD) Scottsdale/Phoenix, AZ

    The purpose of this study is to evaluate the effectiveness and safety of gantenerumab versus placebo in participants with early (prodromal to mild) Alzheimer's Disease (AD). All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 104. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks ...

  • Distraction Apron to Reduce Length of Hospital Stay in Patients Requiring Individual Assignment Nursing Cares Rochester, MN

    The purpose of this study is to determine if the use of a distraction apron will decrease the length of hospital stay in patients with dementia or cognitive impairment.

  • A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease Jacksonville, FL

    This study seeks to evaluate the efficacy and safety of ABBV-8E12 in subjects with Early Alzheimer's Disease.

  • A Study to Develop a Program for those Living Alone with Mild Cognitive Impairment Scottsdale/Phoenix, AZ

    The purpose of this study is to develop a program for individuals living alone with mild cognitive impairment (MCI).

  • Efficacy and Safety Trial of MK-8931 in Participants With Prodromal Alzheimer's Disease (MK-8931-019) Scottsdale/Phoenix, AZ

    The purpose of this trial is to assess the efficacy and safety of MK-8931 compared with placebo in the treatment of amnestic mild cognitive impairment (aMCI) due to Alzheimer's Disease (AD), also known as prodromal AD. Participants will be randomized to receive placebo, or 12 mg or 40 mg MK-8931, once daily. The primary study hypothesis is that at least one MK-8931 dose is superior to placebo with respect to the change from baseline in the Clinical Dementia Rating scale-Sum of Boxes (CDR-SB) score at 104 weeks.

  • Validation of Cognitive Tests in Elderly Cirrhotic Patients Scottsdale/Phoenix, AZ

    The purpose of this study is to define the prevalence and impact of cognitive impairment and their impact on HRQOL in elderly patients with cirrhosis compared to elderly patients without cirrhosis.

  • Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) Scottsdale/Phoenix, AZ

    This study consists of two parts, Part I and Part II. The purpose of Part I of the study is to assess the efficacy and safety of verubecestat (MK-8931) compared with placebo administered for 104 weeks in the treatment of amnestic mild cognitive impairment (aMCI) due to Alzheimer's Disease (AD), also known as prodromal AD. Participants will be randomized to receive placebo, or 12 mg or 40 mg verubecestat, once daily. The primary study hypothesis for Part I is that at least one verubecestat dose is superior to placebo with respect to the change from baseline in the Clinical Dementia ...

  • The Impact of Cognitive Impairment on Driving Safety. Rochester, MN

    Automobile driving is a crucial aspect of everyday life, but driving safety problems including car crashes or speeding violations are a serious public health problem. Alzheimer’s Disease (AD) affects the ability to safely drive and raises crash risk. Mild cognitive impairment (MCI) raises the risk of dementia, and people with MCI have been shown to have problems with memory, decision making, and the ability to concentrate that could lead to unsafe driving, even before obvious dementia begins. Whether MCI patients who continue to drive are safe drivers or not is unknown.

  • Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI and AD Subjects Scottsdale/Phoenix, AZ

    This is a cross-sectional and longitudinal study that will evaluate imaging characteristics of 18F-AV-1451 in cognitively healthy volunteers, mild cognitive impairment (MCI) and Alzheimer's disease (AD) subjects.

  • A Study to Evaluate the Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia with Lewy Bodies Rochester, MN

    The purpose of this study is to evaluate the effect of neflamapimod on cognitive function as assessed in a study-specific Cogstate Neuropsychological Test Battery (NTB).

  • A Study of Specialized Systems in the Brain and How They Relate to the Disease Processes in aMCI and AD Rochester, MN

    This study is being done to learn more about specialized systems in the brain and how they relate to the disease processes in aMCI and AD.

  • Mayo Alzheimer's Disease Research Center Jacksonville, FL; Rochester, MN

    This study is being done to learn more about normal memory and aging, mild memory and thinking problems, Alzheimer's disease and other forms of dementia.

  • A Study to Evaluate the Effects of Voice Therapy on Cognition in the Geriatric Population Jacksonville, FL

    The purpose of this study is to determine if there is a relationship between cognitive status and a patient’s ability to improve vocal quality through effective participation in voice therapy – including following directions within a session and compliance with a home exercise program, and carry-over into daily phonation.

  • Bridging Study of C11 PiB and F18 Flutemetamol Brain PET Rochester, MN

    The intent of this research protocol is to test the equivalency of two amyloid imaging drugs (C11 Pittsburgh Compound B and F18 Flutemetamol). The investigators hypothesize that there will be no significant difference in the distribution of the agents to areas of amyloid deposition in the brain or to other normal brain structures. Recent data have shown similarity in the distribution of the drugs in subjects with AD or mild cognitive impairment (MCI). No comparison data of the two PET drugs in normal subjects has been published. It is important to understand differences in the images and biodistribution from the ...

  • Advancing Reliable Measurement in Alzheimer's Disease and Cognitive Aging Jacksonville, FL

    This study seeks to validate and further develop the NIH Toolbox for Assessment of Neurological and Behavioral Function® (NIHTB) for use in studies of cognitive aging beginning with normal cognition through progression into amnestic Mild Cognitive Impairment (aMCI) and into dementia of the Alzheimer’s Type, early stage (DAT).

  • Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol Jacksonville, FL; Rochester, MN

    Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.

  • Cross-sectional, Multinational, Noninterventional Study to Evaluate the Psychometric Comparability of Culturally Adapted Versions of the Global Preclinical Alzheimer’s Cognitive Composite (G-PACC) Jacksonville, FL

    The main goal of this study is to evaluate whether a certain set of memory and thinking tests that are in English also work in other languages after they are translated. The measures will test your memory, thinking, problem solving, and everyday function abilities.

  • A Study of Early-onset Alzheimer's Disease Jacksonville, FL; Rochester, MN

    The purpose of this Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is designed to look at disease progression in individuals with early onset cognitive impairment . Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EO-nonAD) participants,and (3) cognitively normal (CN) control participants.

  • Mayo Clinic Olmsted Study of Aging (MCSA) Rochester, MN

    This study is being done to learn more about normal memory and aging, mild memory and thinking problems, Alzheimer's disease and other forms of dementia. This study will help us determine how often memory problems occur in people in our community, and help to identify factors that may influence changes in memory and thinking skills.

  • Cerebrospinal Fluid (CSF) Biomarkers for Prediction of Dementia Jacksonville, FL; Rochester, MN

    To further investigate biomarkers in CSF as possible predictors for mild cognitive impairment and dementia

  • A Study to Evaluate MR of CSF Dynamics Rochester, MN

    The purpose of this study is to evaluate changes in CSF dynamics (e.g., velocity, flow rate) between patients with normal pressure hydrocephalus and healthy controls, as well as patients with other dementia disorders.

  • A Study Evaluating the Use of 48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer’s Disease Jacksonville, FL

    The purpose of this study is to characterize and study the relationship of the clinical risk factors and predictors of seizures and epilepsy in patients with Early Onset Alzheimer's Disease (EOAD) using a 48-hour CAA-EEG.

  • A Study to Evaluate Presbycusis and Presbyvestibulopathy and Risk for Mild Cognitive Impairment and Dementia Jacksonville, FL

    The purpose of this study is to examine baseline vestibular and balance problems with cognitive function and diagnosis as compareed to previously studied associations of Presbycusis with cognition function.

  • Advanced Care Planning in Dementia Jacksonville, FL

    The goal of this study is to gain a better understanding of the status of advanced care planning among caregivers of patients with dementia and examine how this differs by race and disease stage.

.

Mayo Clinic Footer